128 related articles for article (PubMed ID: 12917038)
1. [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma].
Zhang DS; Jiang WQ; Li S; Zhang XS; Mao H; Chen XQ; Li YH; Zhan J; Wang FH
Ai Zheng; 2003 Aug; 22(8):870-3. PubMed ID: 12917038
[TBL] [Abstract][Full Text] [Related]
2. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
4. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
5. [Expression of glycoprotein 90K in non-Hodgkin's lymphoma and its clinical significance].
Zhang DS; Ding Y; Li YH; Xu RH; Wang B; Zhang XS; Zeng J; Liang HZ; Jiang WQ
Ai Zheng; 2005 Aug; 24(8):1006-10. PubMed ID: 16086883
[TBL] [Abstract][Full Text] [Related]
6. [A comparative study of VEPA and ACOMEP-BD regimen for the patients with non-Hodgkin's lymphoma].
Kanamori H; Tanabe J; Okamoto R; Tamura T; Fujita H; Murata T; Hashimoto Y; Harano H; Matsuzaki M; Motomura S
Rinsho Ketsueki; 1993 Jun; 34(6):697-704. PubMed ID: 8366571
[TBL] [Abstract][Full Text] [Related]
7. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
8. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
[TBL] [Abstract][Full Text] [Related]
10. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
[TBL] [Abstract][Full Text] [Related]
12. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
13. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy and radiotherapy for non-Hodgkin's lymphomas of the nasal cavity].
Nie DH; Hu WH; Gao YH; Wu Y; Zhang SP
Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):312-4. PubMed ID: 15312373
[TBL] [Abstract][Full Text] [Related]
15. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of 282 patients with non-Hodgkin's lymphoma].
Chen SP; Wu DS; Zhao XL
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):237-9. PubMed ID: 14653077
[TBL] [Abstract][Full Text] [Related]
18. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
19. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
20. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma.
Last KW; Cornelius V; Delves T; Sieniawska C; Fitzgibbon J; Norton A; Amess J; Wilson A; Rohatiner AZ; Lister TA
J Clin Oncol; 2003 Jun; 21(12):2335-41. PubMed ID: 12805335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
